TITLE

Does Cell-Saver Blood Administration and Free Hemoglobin Load Cause Renal Dysfunction?

AUTHOR(S)
Klodell, Charles T.; Richardson, J. David; Bergamini, Thomas M.; Spain, David A.
PUB. DATE
January 2001
SOURCE
American Surgeon;Jan2001, Vol. 67 Issue 1, p44
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Our aim was to evaluate the impact of cell-saver volume and free hemoglobin load on renal dysfunction. Intraoperative blood salvage was conducted in standard fashion, and in each case a sample of the blood was removed for testing. Outcome data on individual patients were collected during a 6-year period (1992-1998). The total amount of free hemoglobin each patient received was calculated. Renal dysfunction was defined as a rise in creatinine level of 1.0 mg/dL above baseline. There were a total of 125 patients who received salvaged blood. The free hemoglobin concentration ranged from 19 to 304 mg/dL (mean, 87.5 mg/dL). Patients were stratified into groups on the basis of the total free hemoglobin received, and the Kruskal-Wallis test demonstrated a difference between groups in the prevalence of renal dysfunction (P < 0.001). A total of 15 patients (12%) had significant postoperative renal dysfunction. There was an association between the amount of free hemoglobin load and subsequent renal dysfunction. This may warrant further study toward establishing policies and limits regarding maximal free hemoglobin blood.
ACCESSION #
5178263

 

Related Articles

  • PLATELET AND GRANULOCYTE TRANSFUSIONS. Hows, J.M.; Brozovic, B. // BMJ: British Medical Journal (International Edition);2/24/90, Vol. 300 Issue 6723, p520 

    Focuses on platelet and granulocyte transfusions. Process in preparing the platelet and granulocyte concentrates; Indication for platelet transfusion; Adverse effects of platelet and granulocyte transfusions.

  • platelet transfusion refractoriness.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1803 

    A definition of the term "platelet transfusion refractoriness," which refers to the inability to increase circulating platelet levels following platelet transfusion, is presented.

  • Therapeutic platelet transfusion safe after autologous stem cell transplantation.  // Hem/Onc Today;1/10/2009, Vol. 10 Issue 1, p16 

    The article presents findings of a study on the safety of using therapeutic platelet transfusion as an alternative to prophylactic platelet transfusion in patients with thrombocytopenia after autologous stem cell transplantation.

  • Low-dose platelet transfusions safe for hypoproliferative thrombocytopenia.  // Hem/Onc Today;1/10/2009, Vol. 10 Issue 1, p17 

    The article presents findings of a study on the safety of using a low-dose prophylactic platelet transfusion in patients with hypoproliferative thrombocytopenia.

  • BEST trial halted due to high rate of severe bleeding following low-dose platelet transfusion. Slichter, Sherrill // Hem/Onc Today;3/25/2009, Vol. 10 Issue 6, p25 

    The article discusses a study which compared low-dose and standard-dose strategies for platelet transfusion.

  • Response to Repeated Platelet Transfusion from the Same Donor. Freireich, Emil J.; Kliman, Allan; Gaydos, Lawrence A.; Mantel, Nathan; Frei III, Emil // Annals of Internal Medicine;Sep63, Vol. 59 Issue 3, p277 

    Reports on the transfusion of platelets to thrombocytopenic patients that could raise the circulating platelet count and arrest hemorrhage. Use of the technique for the short-term treatment of thrombocytopenia associated with serious hemorrhage or for preoperative use; Reasons for the limited...

  • The Threshold for Prophylactic Platelet Transfusions in Adults with Acute Myeloid Leukemia. Rebulla, Paolo; Finazzi, Guido; Marangoni, Francesca; Avvisati, Giuseppe; Gugliotta, Luigi; Tognoni, Gianni; Barbui, Tiziano; Mandelli, Franco; Sirchia, Girolamo // New England Journal of Medicine;12/25/97, Vol. 337 Issue 26, p1870 

    Background: Prophylactic platelet transfusions are usually administered to patients receiving myelotoxic chemotherapy when their platelet count falls below 20,000 per cubic millimeter. Some observations suggest that lower platelet counts can be appropriate in patients in stable condition, but...

  • The Perils of Platelet Transfusions. Kruskall, Margot S. // New England Journal of Medicine;12/25/97, Vol. 337 Issue 26, p1914 

    Editorial. Focuses on the controversies surrounding platelet transfusions in reducing the risk of death from hemorrhage during chemotherapy for leukemia. Problem areas, including collection of platelet product by centrifugation or apheresis; Platelet storage; The lack of a reliable compatibility...

  • CERUS/BAXTER APPLY FOR CE MARK FOR INTERCEPT PLATELET SYSTEM.  // Worldwide Biotech;Feb2001, Vol. 13 Issue 2, p7 

    Reports that Cerus Corp. and Baxter Healthcare Corp. have submitted a CE Mark application for approval to market the Intercept Platelet System in Europe.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics